Skip Navigation LinksHome > March/April 2009 - Volume 15 - Issue 2 > KRAS Mutations and Susceptibility to Cetuximab and Panitumum...
Cancer Journal:
doi: 10.1097/PPO.0b013e31819e3202
Practice of Oncology: Recent Advances

KRAS Mutations and Susceptibility to Cetuximab and Panitumumab in Colorectal Cancer

Jimeno, Antonio MD, PhD; Messersmith, Wells A. MD; Hirsch, Fred R. MD, PhD; Franklin, Wilbur A. MD; Eckhardt, S Gail MD

Collapse Box

Abstract

Recent retrospective evidence from several randomized studies has established that advanced colorectal cancer patients with tumors harboring a mutation in the KRAS gene do not derive benefit from the administration of epidermal growth factor receptor-directed monoclonal antibodies, such as cetuximab or panitumumab. This represents a paradigm-changing event and will have substantial impact on current and future anticancer drug development. These results add to the economic and ethical considerations involved in the development of novel targeted therapies and should increase our scrutiny of mechanisms of resistance and predictive biomarkers while in earlier developmental stages. In this article, we will review the available clinical data and discuss the implications for future drug development in colorectal cancer.

© 2009 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.